Satoshi Anai Selected Research

RK 682

5/2020

Inhibition of Heparanase Expression Results in Suppression of Invasion, Migration and Adhesion Abilities of Bladder Cancer Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Satoshi Anai Research Topics

Disease

50	Neoplasms (Cancer) 01/2022 - 02/2003
45	Prostatic Neoplasms (Prostate Cancer) 02/2022 - 04/2006
23	Carcinoma (Carcinomatosis) 01/2022 - 02/2003
20	Urinary Bladder Neoplasms (Bladder Cancer) 06/2021 - 04/2009
14	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 02/2003
10	Non-Muscle Invasive Bladder Neoplasms 07/2022 - 01/2010
7	Neoplasm Metastasis (Metastasis) 01/2022 - 10/2011
7	Lower Urinary Tract Symptoms 01/2022 - 12/2014
6	Adenocarcinoma 12/2020 - 05/2007
4	Margins of Excision 10/2019 - 11/2007
3	Urologic Neoplasms (Urological Cancer) 04/2022 - 05/2020
3	Infections 08/2021 - 01/2019
3	Carcinogenesis 12/2020 - 03/2010
3	Inflammation (Inflammations) 05/2019 - 01/2017
2	Hypertension (High Blood Pressure) 02/2022 - 02/2016
2	Hypoxia (Hypoxemia) 01/2022 - 03/2011
2	Overactive Urinary Bladder (Overactive Bladder) 01/2022 - 08/2017
2	Pain (Aches) 01/2021 - 05/2020
2	Body Weight (Weight, Body) 07/2020 - 09/2011
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2019 - 01/2018
2	Chronic Renal Insufficiency 12/2019 - 03/2014
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 07/2019 - 05/2018
2	Adenocarcinoma of Lung 01/2018 - 10/2016
2	Carcinoma in Situ 10/2016 - 04/2009
1	Nocturia 07/2022
1	Erectile Dysfunction 02/2022
1	Vesico-Ureteral Reflux (Vesicoureteral Reflux) 01/2022
1	Spinal Dysraphism (Spina Bifida) 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2022
1	Lymphatic Metastasis 01/2022
1	Congenital Abnormalities (Deformity) 01/2022
1	Neurogenic Urinary Bladder (Bladder, Neurogenic) 01/2022

Drug/Important Bio-Agent (IBA)

11	AcidsIBA 01/2022 - 05/2014
11	Prostate-Specific Antigen (Semenogelase)IBA 01/2020 - 04/2006
11	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2005
7	Small Interfering RNA (siRNA)IBA 05/2020 - 04/2009
6	AndrogensIBA 02/2022 - 08/2007
6	Sunitinib (Sutent)FDA Link 01/2022 - 06/2012
5	Gemcitabine FDA Link 01/2022 - 06/2010
5	Axitinib (AG 013736)IBA 01/2022 - 10/2018
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2012 - 10/2007
4	pembrolizumabIBA 01/2022 - 05/2020
4	protoporphyrin IXIBA 01/2022 - 08/2014
4	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 02/2017
4	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 04/2009
4	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 09/2020 - 05/2011
4	Heme Oxygenase-1IBA 03/2016 - 01/2010
3	Adrenergic Receptors (Adrenergic Receptor)IBA 10/2019 - 12/2014
3	Biomarkers (Surrogate Marker)IBA 11/2017 - 05/2014
3	Biological ProductsIBA 10/2016 - 05/2008
2	Testosterone (Sustanon)FDA Link 02/2022 - 01/2020
2	Adenosine Triphosphate (ATP)IBA 01/2022 - 03/2016
2	PlatinumIBA 01/2022 - 12/2018
2	Carboplatin (JM8)FDA LinkGeneric 01/2022 - 01/2012
2	Tamsulosin (Flomax)FDA LinkGeneric 01/2022 - 09/2020
2	silodosin FDA Link 11/2021 - 12/2014
2	naftopidilIBA 11/2021 - 12/2014
2	NitrosaminesIBA 06/2021 - 05/2020
2	Syndecan-1 (Syndecan 1)IBA 05/2020 - 12/2013
2	Docetaxel (Taxotere)FDA Link 01/2020 - 12/2019
2	CytokinesIBA 09/2019 - 04/2019
2	AntibodiesIBA 04/2019 - 01/2019
2	Monoclonal AntibodiesIBA 01/2019 - 07/2005
2	Iodine-125IBA 01/2019 - 08/2017
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 10/2017
2	Flutamide (Eulexin)FDA LinkGeneric 05/2018 - 08/2015
2	Tyrosine Kinase InhibitorsIBA 01/2018 - 03/2010
2	CollagenIBA 11/2017 - 05/2017
2	Everolimus FDA Link 01/2017 - 08/2015
2	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 06/2012
2	NADPH Oxidases (NAD(P)H oxidase)IBA 10/2012 - 10/2011
2	Phosphotransferases (Kinase)IBA 06/2012 - 04/2009
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 03/2011 - 05/2007
2	zinc protoporphyrinIBA 03/2011 - 06/2010
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2010 - 09/2008
2	Green Fluorescent ProteinsIBA 04/2009 - 09/2008
2	OligodeoxyribonucleotidesIBA 07/2007 - 01/2007
1	CreatinineIBA 07/2022
1	HolmiumIBA 04/2022
1	ThuliumIBA 04/2022
1	Muscarinic AntagonistsIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	mirabegronIBA 01/2022
1	N- (4- ((5- (hydroxy(phenyl)methyl)pyrrolidin- 2- yl)methyl)phenyl)- 4- oxo- 4,6,7,8- tetrahydropyrrolo(1,2- a)pyrimidine- 6- carboxamideIBA 01/2022
1	Adrenergic Antagonists (Antiadrenergic Agents)IBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 08/2021

Therapy/Procedure

30	Therapeutics 07/2022 - 02/2003
18	Brachytherapy 02/2022 - 09/2012
13	Radiotherapy 01/2022 - 10/2006
11	Drug Therapy (Chemotherapy) 01/2022 - 01/2007
9	Prostatectomy (Retropubic Prostatectomy) 11/2021 - 05/2007
9	Nephrectomy 08/2021 - 02/2003
6	Cystectomy 10/2019 - 01/2016
5	Transurethral Resection of Bladder 02/2021 - 03/2016
3	Nephroureterectomy 01/2021 - 05/2019
3	Castration 01/2020 - 04/2014
2	Oral Administration 06/2021 - 06/2015
2	Operative Time 01/2021 - 02/2019
2	Neoadjuvant Therapy 10/2019 - 04/2018
1	Laser Therapy (Surgery, Laser) 04/2022